Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data

Khurum Khan1,*, Reyes Gonzalez-Exposito2, David Cunningham2,*, Dow-Mu Koh3, Andrew Woolston4, Louise Barber1, Beatrice Griffiths4, Kyriakos Kouvelakis2, Vanessa Calamai2, Monia Balli3, Nasir Khan1, Annette Bryant2, Claire Saffery2, Charles Dearman2, Ruwaida Begum2, Sheela Rao2, Naureen Starling2, David Watkins2, Ian Chau2, Chiara Braconi2, Nicola Valeri2,5, Marco Gerlinger2,4 and Nicos Fotiadis3

1 Department of Gastrointestinal Oncology, UCL Cancer Institute, University College NHS Foundation Trust, London, United Kingdom, 2 Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom, 3 Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom, 4 Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom, 5 Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom

*Correspondence: Khurum Khan khurum.khan1@nhs.net
David.Cunningham@rmh.nhs.uk, Nicos.Fotiadis@rmh.nhs.uk

Specialty section:
This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology.

Received: 14 April 2020
Accepted: 27 July 2020
Published: 04 September 2020

Background: Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic analyses.

Patients and Methods: All consecutive patients who underwent plugged image-guided biopsy at Royal Marsden from June 2013 until September 2016 were included in the analysis. In the next step, a second cohort of patients prospectively treated within two clinical trials (PROSPECT-C and PROSPECT-R) were assessed for the DNA yield from biopsies assessed for complex genomic analysis.

Results: A total of 522 plugged core biopsies were performed in 457 patients [men, 52%; median age, 63 years (range, 17–93)]. Histological diagnosis was achieved in 501 of 522 (96%) performed biopsies. Age, gender, modality, metastatic site, and seniority of the interventionist were not found to be significant factors associated with odds of failure on a logistic regression. Seventeen (3.3%) were admitted due to biopsy-related complications; nine, three, two, one, one, and one were admitted for grade I/II pain control, sepsis, vasovagal syncope, thrombosis, hematuria, and deranged liver functions, respectively; two patients with right upper quadrant pain after liver biopsy were found to have radiologically confirmed subcapsular hematoma requiring conservative treatment. One patient (0.2%) developed grade III hemorrhage following biopsy of a gastric gastrointestinal stromal tumor (GIST). Overall molecular analysis was successful in 89% (197/222 biopsies). Prospective validation in 62 biopsies gave...
INTRODUCTION

While cancer management and treatment options have significantly improved during the last few years, our knowledge and understanding about mechanisms of response, and/or resistance to anticancer therapies remain relatively sparse. To date, this relative lack of understanding is partially due to difficulties in accessing prospectively collected tissue and blood samples from systemic anticancer therapy (SACT)-resistant tumors.

Image-guided tissue biopsies are not just important in establishing an accurate histopathological diagnosis and standard cancer management; high-yield samples are also vital in understanding the molecular and genomic characteristics of tumors. Genomic analyses on tumor samples broadly fall into two categories including (1) targeted approaches investigating a limited number of genes that are known to influence clinical decision making and (2) whole exome or genome sequencing frequently adopted in exploratory research studies to learn about new mechanisms of response or resistance to SACT (1, 2). Conventional formalin-fixed paraffin-embedded (FFPE) samples obtained during diagnostic procedures may not be sufficient for such analyses to be realized. For instance, the data from The Cancer Genome Atlas (TCGA) studies showed that fresh frozen material from primary tumor resection specimens was associated with a tumor content of 60% (3). Moreover, using FFPE DNA for large-scale genomic studies may demonstrate mutations that have occurred as a result of the fixation process, which makes it difficult to distinguish real tumor variants from these fixation artifacts. Furthermore, low-quality fragmented DNA can fail quality control in the preanalytical stage impairing success rates.

While a number of retrospective studies have demonstrated the safety and accuracy of diagnostic biopsies (4–6), data interpretation from such studies has often been hampered by small numbers, the lack of information on yield for molecular/genomic characterization of tumors, and the lack of prospective validation. At Royal Marsden (RM), we have been using coaxial core-needle biopsy (CNB) system and a preformed gelatin sponge sealing device to conduct solid organ core biopsies in order to minimize the number of passes and reduce the risk of complications, respectively. We present here the largest dataset demonstrating the safety and accuracy of this approach. Moreover, we took the opportunity to utilize a cohort of patients from two prospective clinical trials to validate tumor yields from biopsies in these translational studies.

MATERIALS AND METHODS

Study Design

All consecutive patients who underwent plugged image-guided biopsy at RM from June 2013 until September 2016 were included in the analysis. Data including gender, age, primary tumor, biopsy site, needle gage, interval between biopsy and discharge, incidence of complications, and biopsy success were collected. The study was approved by the RM Institutional review board.

Biopsy Technique

The biopsies were performed by a Consultant Interventional Radiologist (IR) or an IR fellow under supervision. Ultrasound and CT guidance was used based on the location of the lesion. Conscious sedation was administered along with local anesthesia, when required, to maximize cooperation and improve patient experience (Figure 1). A 15- or 17-G coaxial needle was inserted under direct image guidance at the edge of the lesion and two to six cores were obtained with a 16- or 18-G automatic core-biopsy needle (True-Core II, Argon Medical Devices, Frisco, TX, United States), respectively. Different areas inside the lesion were sampled by changing the angle and position of the coaxial needle. After the samples were collected, one to four preformed 16- or 18-G gelatin foam pledgets (Hunter biopsy-sealing device, Vascular Solutions Inc., Minneapolis, MN, United States) were deployed through the coaxial along the tract of the needle to facilitate hemostasis. The gelatin resorbs completely within 12 weeks.

Validation Cohort

In the second step, a validation cohort of patients prospectively treated within two clinical trials was used to assess the DNA yield utilized for genomic analysis. The two trials included PROSPECT-C [clinical trials.gov number (NCT02994888)] (2, 7) and PROSPECT-R [clinical trials.gov number (NCT03010722)] (1); phase II, open label, non-randomized studies of antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies and regorafenib in patients with RAS wild type and RAS mutant refractory metastatic colorectal cancer (CRC), respectively. All participants in both studies were required
FIGURE 1 | Biopsy examples of patients within the study (A) A computed tomography (CT) of a patient with a highly vascular retroperitoneal mass thought to be too high risk to biopsy at the local hospital. Surgery was also considered to be high risk of R1/R2 resection, and a CT-guided biopsy was recommended by our multidisciplinary team (MDT). (B) Biopsy was performed with a 15-G/16-G coaxial needle. The tract was plugged with 16-G Hunter plugs, and there were no complications. The biopsy showed an inflammatory myofibroblastic tumor, which responded well on steroids and an operation was avoided. (C) PET/CT of a 57-year-old patient with relapsed Hodgkin’s lymphoma after six cycles of ABVD chemotherapy. There was response in all sites of disease with the exception of a plaque of tissue behind the fundus of the stomach, which appear [18F]fluorodeoxyglucose (FDG) avid on PET scan. A decision of the MDT was made to biopsy the lesion in order to exclude transformation of lymphoma. (D) The 17-G coaxial needle was placed medial to the left adrenal and above the splenic vessels adjacent to the lesion. Three cores were taken, and the tract was plugged. There were no complications. The biopsy showed Hodgkin’s lymphoma, which responded well to systemic therapy and consolidation RT. (E) Coronal CT images of a 48-year-old patient with a large tumor of the inferior vena cava (IVC) extending from the level of the renal veins to the right atrium. Occluded hepatic veins and ascites can be seen on the scan. (F) The lesion was biopsied with a 15-G/16-G coaxial needle. (G) The tract was plugged with three gelfoam pledgets. A diagnosis of leiomyosarcoma of the IVC was made, and the procedure had no complications.
to have mandatory pretreatment biopsies (6 cores), biopsies at partial response in PROSPECT-C and stable disease at 2 months in PROSPECT-R (6 cores), and at the time of progression (6–12 cores from two suitable progressing metastatic sites).

**Prospective Tissue Collection Procedures**

Fresh frozen and FFPE tissue samples were obtained, and plasma collection was conducted as per the study protocols at the clinically relevant defined time points. Sixteen-gage core biopsy was used to collect three or four fresh biopsy specimens and one or two specimens fixed in formalin and paraffin embedded. Within the trials, approximately 25% of the total length of a core was detached for primary culture, and the remaining ∼75% of the core was snap frozen and used for genomic analysis. One core was transported to establish tumor-derived organoids and targeted panel validation (8). One core was used for genomic analysis after being placed into cryovials and immediately snap frozen in liquid nitrogen. The remaining two cores were placed straight into formalin and embedded in paraffin wax. Primary morphological and immunohistochemical analysis was performed by the histopathologist on the FFPE specimen for confirmation of diagnosis. The samples were then stored in the GI and Lymphoma Research Bank of the RM, anonymized by trial number and time point.

**Tissue Sample Processing**

Biopsy cores were snap frozen in liquid nitrogen at the time of collection. Genomic gDNA and mRNA were co-extracted from cores using the Qiagen All-Prep kit. DNA was also isolated from whole blood samples using the Qiagen QIAamp DNA Blood Mini kit (Figure 2).

**Whole Exome Sequencing**

A minimum of 500 ng of gDNA was prepared for whole exome sequencing (WES) using the Agilent SureSelect Human All Exon v5 capture library, according to the manufacturers' protocol. The resulting libraries were sequenced to a mean depth of 100× using paired-end 100 reads on an Illumina HiSeq 2500. High-quality reads were aligned to the National Center for Biotechnology information (NCBI) reference genome (hg19) using BWA (v0.7.12) and SAMtools (v0.1.19) to remove duplicates. Tumor content was estimated based on the CNVkit (v0.8.1) copy number profile.

**Sanger Sequencing**

For patients with a known tumour variant, PCR was performed on 20 nanograms of gDNA using M13F/R-tailed mutation specific primers (Life Technologies; Supplementary Table 1) and Q5 High-Fidelity 2 × Master Mix (NEB) on an Eppendorf Mastercycler Nexus GSX1. Primer-specific annealing temperatures for Q5 polymerase were established using the NEB online Tm calculator. PCR products were cleaned using Qiaquick PCR purification kit (Qiagen), and 15 ng DNA was submitted for M13F and M13R sequencing using the Mix2Seq service (Eurofins Genomics). Ab1 traces were visualized and compared to the reference sequence using ApE software1. Sample tumour content was estimated from the relative abundance of wild-type and variant peaks (Figure 3 and Supplementary Table 1).

**Statistical Design**

The success rate of biopsies was determined by the ability to perform standard molecular testing on tissue specimens and safety determined by frequency of complications and extended hospital stay. Encrypted data were collected in a password-protected Excel file and statistical analysis performed using STATA13. Chi-squared analysis was undertaken to identify baseline characteristics that provided independent association with failure and success rates.

**RESULTS**

**Overall Safety of Image-Guided Biopsies and Cox Regression Analysis**

A total of 522 tissue biopsies were performed in 457 patients [men, 48%; median age, 63 years (range, 23–86)] (Supplementary Table 2). Two, three, and four biopsies were obtained from 51 (11.2%), 13 (2.8%), and 1 (0.2%) patients, respectively, at different time points as part of clinical trial protocols. Histological diagnosis was achieved in 501 of 522 (96%) performed biopsies. Same-day discharge was achieved for 444 (85.1%) procedures as outpatients, 35 (6.7%) and 17 (3.3%) had planned inpatient and elective procedures, respectively, and 8 (1.5%) patients were kept in for overnight observation after a late evening procedure. Seventeen (3.3%) were admitted with the following biopsy-related complications: grade I/II pain control (nine), sepsis (one), vasovagal syncope (two), thrombosis (one), hematuria (one), and deranged liver functions (one). Two patients with right upper quadrant pain had radiologically confirmed subcapsular hematoma requiring conservative treatment. One patient (0.2%) developed grade III hemorrhage requiring transfusion of 2 U of packed red blood cells following biopsy of a gastric gastrointestinal stromal tumor (GIST). In 21 of 522 biopsies, diagnosis was not achieved due to sampling error during needle placement. These were small lesions not well visualized with ultrasound and CT, and normal tissue adjacent to the lesion was consequently biopsied. When patients were divided into two groups including those who underwent “liver biopsy” (n = 284 biopsies from 231 patients) and all other biopsies except liver, i.e., “others” (n = 238 biopsies from 228 patients), success rates of 95.02 and 98.32% were observed in the two groups, respectively (Supplementary Tables 3A,B).

**Chi-Squared Tests to Assess Covariates of Failure**

Results from chi-squared tests showed that the covariates of age category at earliest biopsy date, gender, modality

---

1[https://openwetware.org/mediawiki/index.php?title=ApE_-_A_Plasmid_Editor_(software_review)&oldid=753142]
of image guidance, metastatic site, and seniority of the interventionist were not associated with the occurrence of failure. Association of site of biopsy (others vs. liver), however, showed a significant trend in favor of other organs vs. liver, although the difference was not found to be numerically and clinically of significant impact \((p = 0.053)\). Patients who had biopsy within clinical trials \((n = 163\) biopsies) vs. those who underwent routine clinical diagnostic biopsies \((n = 338)\) showed a success rate of 98.79 and 95.48\%, respectively. Chi-squared test demonstrated significance in favor of patients treated within clinical trials \((p = 0.07; \text{Supplementary Table 4})\).

**Validated Genomic Testing in Patients With Metastatic Colorectal Cancer**

Given that metastatic colorectal cancer (mCRC) patients underwent genomic profiling for clinically actionable mutations such as \(\text{KRAS}, \text{NRAS},\) and \(\text{BRAF}\) analysis routinely with a clinically validated COBAS panel, we rationalized separating this
cohort from the remaining patients. Of the total 144 patients with mCRC, 17 repeat charts and 38 patients who were referred from other hospitals were excluded. Of the remaining 89 patients, 2 (2.25%) had a failed molecular analysis due to insufficient DNA extraction—29 (32.58%), 6 (6.74%), and 3 (3.37%) were found to have KRAS exons 2–4, NRAS exons 2–4, and BRAF v600 mutations, respectively. Moreover, 36 patients were tested for TP53 and PIK3CA mutation; 26 (72.22%); and 5 (13.89%) were
found to have these mutations, respectively. These results are largely consistent with previously published literature.

**gDNA Extraction From Biopsy: A Cohort of PROSPECT-C and PROSPECT-R Studies**

DNA was extracted from 62 biopsies taken from our prospective PROSPECT-C and PROSPECT-R trials and in 65% of cases; sufficient gDNA for WES was achieved from a single core. Two or three tissue cores were needed to yield sufficient DNA for 27 and 8% of the biopsy time points, respectively (Supplementary Figure 1). When required, utilizing all available tissue cores allowed gDNA extraction rate of 100%. Tumor content was determined for 62 biopsies (75.61%) in the analyzed cohort and was estimated as >20% in 79.03% of cases (Table 1).

**Assessment of Biopsy Tumor Content**

All patients entering the PROSPECT trials were tested for KRAS/NRAS mutations in the archival tumor biopsy by standard COBAS methodology, as this precluded entry into PROSPECT-C study (2). As a result, all patients entering the PROSPECT-R trial had a cataloged KRAS/NRAS variant that could be used to investigate the tumor content of the respective biopsy samples (1). Mutation profiles for KRAS/NRAS have previously been shown to be highly concordant between samples from the same colorectal tumor (9). We therefore estimated the cancer cell content of biopsy samples using Sanger sequencing to detect the likely truncal KRAS/NRAS mutations identified previously by clinical sequencing assays. Samples were scored according to the following criteria: “high” tumor content if the variant base was detected at an intensity exceeding or equal to the wild-type base; “medium” if the variant base was detected at >25% of the intensity of the wild-type base; “low” if the variant base was clearly detected above background but at <25% of the intensity of the wild-type base; and “not detected” if the variant base could only be detected within the background noise or not at all (Table 2 and Figure 3). Further cores were extracted and sequenced if the first had low or no detectable tumor content (Table 2). In five cases, an additional core had medium tumor content where the first tested core has low/not detectable tumor content. Out of the 49 samples tested, 39 were scored as medium or high tumor content (Table 2).

**DISCUSSION**

Tissue biopsies are often considered as the gold standard for diagnostic and research purposes; however, there are many logistical, technical, and ethical challenges in the successful appliance of tissue biopsies in the clinic. To our knowledge, we present the largest dataset of tissue biopsies with a prospective validation cohort demonstrating high tumor yield and ability to perform genomic analysis via image-guided tissue sampling (10, 11).

Biomarker discovery requires validation in prospective clinical trials; however, tissue collection procedures need to be optimized such that the valuable tissue obtained during trials is processed successfully (12, 13). Moreover, even within a resource-friendly environment, molecular profiling studies have often suffered due to inadequacy of samples; failure rates reportedly vary between 15 and 33% (14–17). Keeping these issues in view, we ensured that prebiopsy scans were discussed in person with a radiologist, and only the most amenable lesions were chosen for pretreatment biopsies; experienced radiologists were then able to target multiple cores (6) from the periphery of the chosen lesions. The current study demonstrates that a strong infrastructure and good communication allows high-quality tumor samples to be obtained in a time-efficient manner. The coaxial biopsy technique used at the RM has the advantage of puncturing the capsule of solid organs (liver, kidney, spleen) only once, minimizing

---

**TABLE 1** DNA extraction and estimated tumor content.

|                    | PROSPECT-C | PROSPECT-R | Total |
|--------------------|------------|------------|-------|
| Number of BL       | 15         | 31         | 46    |
| Number of PD       | 15         | 21         | 36    |
| Number of pairs (BL/PD) | 7          | 19         | 26    |
| Attempted DNA extraction (total) | 30        | 33         | 63    |
| Attempted DNA extraction (BL) | 15       | 31         | 46    |
| Attempted DNA extraction (PD) | 15      | 2          | 17    |
| Attempted DNA extraction (pairs BL/PD) | 7       | 2          | 9     |
| DNA yield > 1 µg (total) | 27       | 31         | 58    |
| DNA yield > 1 µg (BL)  | 13         | 29         | 42    |
| DNA yield > 1 µg (PD)  | 14         | 2          | 16    |
| DNA yield > 1 µg (pairs BL/PD) | 6         | 2          | 8     |
| Estimated tumor content (total) | 30       | 32         | 62    |
| ≥20%                | 22         | 27         | 49    |
| <20%                | 8          | 5          | 13    |
| Estimated tumor content (BL) | 15       | 31         | 46    |
| ≥20%                | 11         | 27         | 38    |
| <20%                | 4          | 4          | 8     |
| Estimated tumor content (PD) | 15       | 1          | 16    |
| ≥20%                | 11         | 0          | 11    |
| <20%                | 4          | 1          | 5     |
| Estimated tumor content in BL/PD pairs | 7       | 1          | 8     |
| ≥20%                | 4          | 0          | 4     |
| <20%                | 3          | 1          | 4     |

**Table 2** Sample tumor content estimated from Sanger sequencing.

|                    | PROSPECT-R |
|--------------------|------------|
| Number of samples sequenced: | 49         |
| Number of cores sequenced per sample: | 1 core: 35  |
| 2 cores: 10          |
| 3 cores: 4           |
| Number of high tumor content cores: | 12         |
| Number of medium tumor content cores: | 27         |
| Number of low tumor content cores: | 6          |
| Number of cores with no detectable tumor content: | 22         |

BL, baseline; PD, progressive disease.
the injury to normal tissues, improving patient experience, and at the same time acquiring multiple large cores for diagnosis and molecular analysis. The application of preformed gelatin sponge sealing device at the biopsy tract provides a mechanical matrix that facilitates clotting. Gel foam pledgets, due to their bulk, surface-acting hemostatic agents, slow the flow of blood, protect the forming clot, and offer a framework for the deposition of the cellular elements of blood, decreasing the risk of major bleeding. The grade III hemorrhage in our series was only 0.2%, which compares favorably with the 0.5–2% seen in large series in the literature using Tru-Cut needles with or without coaxial technique.

Common concerns about trials mandating research biopsies include the lack of patient understanding about the purpose of such studies and the potential risks associated with additional interventional procedures within the research protocols. In the case of our PROSPECT-C trial, patients included in the study had access to anti-EGFR antibody treatment via the cancer drug fund (CDF) independent of the research biopsy findings, which meant that the research biopsies were of no direct patient benefit. In order to ensure that patients clearly understood the purpose of their participation in PROSPECT-C and other research studies, a prospective patient-based survey at the RM was performed. Remarkably, it showed that most patients who consented to a research biopsy gave an altruistic reason (e.g., to help research and/or others) as to why they agreed to participate. A common concern regarding trial-related invasive intervention is procedure-related complications. Notably, the biopsy complication rates in more than 500 patients in our cohort (including patients on PROSPECT studies) were extremely low and compared favorably with published literature. The technical reasons for success can be attributed to the use of large gauge coaxial needles, which enable multiple tissue cores to be sampled with a single pass. Subsequent application of gelatin foam pledgets via a coaxial cannula at withdrawal effectively seals the biopsy track and minimizes hemorrhage (<1%), thus enabling safe same-day discharge in the majority of patients. This technique, however, needs to be carefully considered in appropriate patients; for example, any attempt to biopsy lung parenchyma would carry a significant risk of the gel foam pledget deploying in a pulmonary vein resulting in systemic embolus. We, however, acknowledge that the exceptional safety observed in our cohort may not be reproducible in a less resource-friendly environment, as it is highly operator dependent, and thus, clinicians are encouraged to audit their own data when determining the need for requesting tissue biopsies.

Following the safe acquisition of biopsy material, the processing of tumor samples has its own challenges. First, the acquired sample contains a mixture of cancer cells and stroma (connective tissue, blood vessels, and inflammatory cells). It is well established that stromal infiltration may lead to problems in interpreting genomic data. In contemporaneous studies conducted at the RM (e.g., FOrMAT study), sample failure rates were high with only 16% of samples showing tumor content of >50%. The FOrMAT study collected a range of GI tumor samples including pancreatic cancers, which are more likely to be dominated by inflammatory and stromal cells but relied on using only FFPE tissues. FFPE tissue has limitations for complex genomic studies, as the DNA yield and quality are affected by the process of fixation and paraffin embedding. The PROSPECT studies benefited from parallel analysis using both FFPE and fresh frozen tissue, where the former was used for pathological assessment and the latter for molecular characterization and genomic analysis. By utilizing all available tissue cores as required, we achieved a gDNA extraction of >90% and an estimated tumor content of >20% in 87.27% of the cases. These data compare favorably with a recent large-scale study comprising of >10,000 patients, who were subjected to a hybridization-based next-generation sequencing (NGS) panel capable of detecting all-protein coding mutations, copy number alterations, and selected promoter mutations and structural rearrangements.

We next took into account the limitations of tumor estimates generated by subjective pathological assessment of tumor morphology and cellularity estimates. Cellularity can be estimated by quantifying the mutant alleles using technologies, such as Sanger or Ion Torrent sequencing, but this requires prior knowledge of the mutation. In PROSPECT-R, Sanger sequencing was used to assess tumor content, as RAS mutation was a prerequisite for entry into the study. However, only patients with no known RAS pathway mutation could participate in PROSPECT-C, so alternative techniques were required for tumor cellularity estimates. An unbiased statistical approach that directly measures tumor content from the DNA sample, therefore, allowed us to take into account factors such as tumor ploidy and intratumor heterogeneity (ITH). This study highlights the safety of tissue biopsies and has significant clinical implications in the management of various malignancies—repeat biopsies should be considered in clinically relevant cases, for example at the time of progression on targeted therapies. Moreover, recent data by our group and others have demonstrated strong concordance between solid and liquid biopsies, and thus, the latter can be considered where a clinically validated panel is available and answers the relevant clinical question.

**CONCLUSION**

Oncologic management and clinical trial participation require accurate histological and molecular characterization. Image-guided biopsies using large gauge coaxial needles enable multiple tissue cores to be obtained with a single pass. This increases the probability of diagnostic success for complex molecular analysis. Applying gelatin foam pledgets via the coaxial cannula following biopsy to seal the track reduces hemorrhagic risk and enables safe same-day discharge in the majority of patients. By successfully obtaining sufficient number of tumor tissue samples within prospective trials, such studies can further the
understanding of tumor biology and help develop biomarkers of clinical and translational relevance. Ultimately, this will enhance the application of personalized medicine in the clinic.

**AUTHOR’S NOTE**

This work was presented in ESMO 2017 and the abstract was published in Annals of Oncology in supplements.

**DATA AVAILABILITY STATEMENT**

The accession number for the DNA and RNA sequencing data reported in this manuscript is European Genome-phenome Archive: EGAS00001003367 and EGAD00001004501.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Royal Marsden Research and Ethics Committee. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the article and approved the submitted version.

**FUNDING**

The authors acknowledge support from the National Institute for Health Research Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.01634/full#supplementary-material

**REFERENCES**

1. Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, et al. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut. (2017) 67:1484–92. doi: 10.1136/gutjnl-2017-314178
2. Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. (2018) 8:1270–85. doi: 10.1158/2159-8290. cd-17-0891
3. Cancer Genome Atlas Network. TCGA Tissue Sample Requirements: High Quality Requirements Yield High Quality Data. (2016). Available online at: https://www.cancerresearchuk.org/sites/default/files/smp1_booklet_1.2_-_no_marks.pdf (accessed August 14, 2020).
4. Hsu MY, Pan KT, Chen CM, Lui KW, Chu SY, Lin YY, et al. CT-guided percutaneous core-needle biopsy of pancreatic masses: comparison of the standard mesenteric/retroperitoneal versus the trans-organ approaches. Clin Radiol. (2016) 71:507–12. doi: 10.1016/j.crad.2016.02.021
5. Olson MC, Atwell TD, Harmen WS, Konrad A, King RL, Lin Y, et al. Safety and accuracy of percutaneous image-guided core biopsy of the spleen. AJR Am J Roentgenol. (2016) 206:655–9. doi: 10.2214/ajr.15.15125
6. Ocak S, Duplaquet F, Jamart J, Pirard L, Weynand B, Delos M, et al. Diagnostic accuracy and safety of CT-guided percutaneous transthoracic needle biopsies: 14-Gauge versus 22-gauge needles. J Vasc Int Radiol JVIR. (2016) 27:674–81. doi: 10.1016/j.jvir.2016.01.134
7. Woolston A, Khan K, Spain G, Barber IJ, Griffiths R, Gonzalez-Exposito R, et al. Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during Anti-EGFR treatment in colorectal cancer. Cancer Cell. (2019) 36:35–50.e9. doi: 10.1016/j.ccell.2019.05.013
8. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science (New York N Y). (2018) 359:920–6.
9. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. (2014) 15:454.
10. Khan K, Gonzalez Exposito R, Cunningham D, Koh DM, Woolston A, Kouvelakis K, et al. Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominantly gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. Ann Oncol. (2017) 28(Suppl. 3):ii16. doi: 10.1093/annonc/mdx263.014
11. Khurum K, Gonzalez-Exposito R, Cunningham D, Koh D, Woolston A, Barber I, et al. Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in Oncology patients treated in a specialist cancer centre with prospective validation within clinical trial data. medRxiv. (2020). [Preprint]. doi: 10.1101/2020.04.17.20065458
12. Diamandis M, White NM, Youssef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. (2010) 8:1175–87. doi: 10.1158/1541-7786.mcr-10-0264
13. Wistuba II, Gelovani JG, Jacoby JF, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol. (2011) 8:315–41. doi: 10.1038/nrclinonc.2011.2
14. Ferté C, Massard C, Illena H, Houlbecque A, Lacroix L, Ammari S, et al. Abstract CT240: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Cancer Res. (2014) 74:CT2140.
15. Andre F, Bachelot T, Commvo F, Campone M, Arnedos M, Diers V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. (2015) 14:267–74. doi: 10.1016/ s1470-2045(13)70611-9
16. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. (2015) 33:2753–62. doi: 10.1200/jco.2014.60.4165
17. Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Comparative targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, non-inferiority, randomised controlled phase 2 trial. Lancet Oncol. (2015) 16:1324–34.
18. Lungren MP, Lindquester WS, Seidel FG, Kothary N, Monroe EJ, butterflies; Taylor J, et al. Ultrastructural-guided liver biopsy with gelatin sponge pledget tract localization in infants weighing less than 10 kg. J Pediatr Gastroenterol Nutrit. (2016) 63:e147–51. doi: 10.1097/mpp.0000000000001429
19. Atwell TD, Smith RL, Hasley GK, Callstrom MR, Schleck CD, Harmsen WS, et al. Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. *Air Am J Roentgenol.* (2010) 194:784–9. doi: 10.2214/ajr.08.2122

20. Lipnik AJ, Brown DB. Image-guided percutaneous abdominal mass biopsy: technical and clinical considerations. *Radiol Clin North Am.* (2015) 53: 1049–59.

21. Pentz RD, Harvey RD, White M, Farmer ZL, Dashevskaya O, Chen Z, et al. Research biopsies in phase I studies: views and perspectives of participants and investigators. *Irb.* (2012) 3:41–8.

22. Olson EM, Lin NU, Krop IE, Winer EP. The ethical use of mandatory research biopsies. *Nat Rev Clin Oncol.* (2011) 8:620–5. doi: 10.1038/nrclinonc.2011.114

23. Saggese M, Dua D, Simmons E, Lemech C, Arkenau H. Research biopsies in the context of early phase oncology studies: clinical and ethical considerations. *Oncol Rev.* (2013) 7:e5. doi: 10.4081/oncol.2013.232

24. Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. *J Clin Oncol Off J Am Soc Clin Oncol.* (2010) 28:2635–40. doi: 10.1200/jco.2009.27.2443

25. Moorcraft SY, Begum R, Cunningham D, Peckitt C, Baratelli C, Gillbanks A, et al. Attitudes of patients with gastrointestinal cancers toward research biopsies. *Clin Colorectal Cancer.* (2016) 16:e181–9. doi: 10.1016/j.ccc.2016.09.008

26. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, et al. Factors associated with success of image-guided tumour biopsies: results from a prospective molecular triage study (MOSCATO-01). *Eur J Cancer.* (2016) 59:79–89. doi: 10.1016/j.ejca.2016.02.006

27. Howlett DC, Drinkwater KJ, Lawrence D, Barter S, Nicholson T. Findings of the UK national audit evaluating image-guided or image-assisted liver biopsy. Part II. Minor and major complications and procedure-related mortality. *Radiology.* (2013) 266:226–35. doi: 10.1148/radiol.12120224

28. Laird PW. Principles and challenges of genomewide DNA methylation analysis. *Nat Rev Genet.* (2010) 11:191–203. doi: 10.1038/nrg2732

29. Song S, Nones K, Miller D, Harliwong I, Kassahn KS, Pinese M, et al. qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. *PLoS One.* (2012) 7:e45835. doi: 10.1371/journal. pone.0045835

30. Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, et al. Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. *Ann Oncol Off J Eur Soc Med Oncol.* (2018) 29:230–6. doi: 10.1093/annonc/mdx631

31. Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J. Tumor microenvironment and progression of pancreatic cancer. *Exp Oncol.* (2010) 32:128–31.

32. Koshiba M, Ogawa K, Hamazaki S, Sugiyama T, Ogawa O, Kitajima T. The effect of formalin fixation on DNA and the extraction of high-molecular-weight DNA from fixed and embedded tissues. *Pathol Res Pract.* (1993) 189:66–72. doi: 10.1016/s0344-0338(11)80118-4

33. Howat WJ, Wilson BA. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. *Methods.* (2014) 70:12–9. doi: 10.1016/j. ymeth.2014.01.022

34. Zokla V, Baumann M, Cathomas G. Effect of buffered formalin on amplification of DNA from paraffin wax embedded small biopsies using real-time PCR. *J Clin Pathol.* (2004) 57:654–6. doi: 10.1136/jcp.2003.013961

35. Cree IA, Deans Z, Ligenzberg MJ, Normanno N, Edsjo A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. *J Clin Pathol.* (2014) 67:923–31. doi: 10.1136/jclinpath-2014-202404

36. Cancer Research UK. *CRUK Stratified Medicine Program.* (2016). Available online at: http://wwwcancerresearchukorg/sites/default/files/smp1_booklet_ 12_-_no_markspdf (accessed May 14, 2016).

37. Zehir A, Renavod R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med.* (2017) 23:703–13.

38. Rothberg MJ, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. *Nature.* (2011) 475:348–52.

**Conflict of Interest:** DC received research funding from Roche, Amgen, Celgene, Sanofi, Merck Serono, Novartis, AstraZeneca, Bayer, Merrimmack, and MedImmune. IC has had advisory roles with Merck Serono, Roche, Sanofi Oncology, Bristol Myers Squibb, Eli-Lilly, Novartis, and Gilead Science. He has received research funding from Merck-Serono, Novartis, Roche and Sanofi Oncology, and honoraria from Roche, Sanofi-Oncology, Eli-Lilly, and Taiho. KKh has advisory role with Bayer Oncology group. NV received honoraria from Merck Serono, Bayer, and Eli-Lilly.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Khan, Gonzalez-Exposito, Cunningham, Koh, Woolston, Barber, Griffiths, Kouvelakis, Calamai, Bali, Khan, Bryant, Safery, Dearman, Begum, Rao, Starling, Watkins, Chau, Braconi, Váler, Gerlinger and Fotiadis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.